Loading tape…Loading tape…
Eli Lilly and Company
LLY
LLY
Eli Lilly has reported that its new drug drives comprehensive disease control in ulcerative colitis patients, according to benzinga.com. Financially, the company operates with a market cap of approximately $1.08 trillion and generates an annual revenue of $65,179,000,000. It also trades at a PE ratio of 38.47, supported by an EPS TTM of 29.93 and a free cash flow yield of 1.85%.
Based on benzinga.comIf a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything
Eli Lilly Says New Drug Drives Comprehensive Disease Control in Ulcerative Colitis Patients
Lilly confirms date and conference call for third-quarter 2026 financial results announcement
New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.